AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Bausch + Lomb Corporation operates as an eye health company worldwide.
It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical.
The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye.
The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use.
The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices.
The company was founded in 1853 and is headquartered in Vaughan, Canada.
Country | CA |
IPO Date | May 6, 2022 |
Industry | Medical - Instruments & Supplies |
Sector | Healthcare |
Employees | 13,000 |
CEO | Brenton L. Saunders J.D. |
Contact Details
Address: 520 Applewood Crescent Vaughan, ON CA | |
Website | https://www.bausch.com |
Stock Details
Ticker Symbol | BLCO |
Exchange | NYSE |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001860742 |
CUSIP Number | 071705107 |
ISIN Number | CA0717051076 |
Employer ID | 00-0000000 |
SIC Code | 3851 |
Key Executives
Name | Position |
---|---|
Brenton L. Saunders J.D. | Chief Executive Officer & Chairman |
A. Robert D. Bailey | Executive Vice President & Chief Legal Officer |
Osama A. Eldessouky | Executive Vice President & Chief Financial Officer |
Alan Waterhouse CPFA, MBA | Executive Vice President and Chief Supply Chain & Operations Officer |
Andrew Stewart | President of Global Pharmaceuticals & International Consumer |
Dr. Manisha A. Narasimhan Ph.D. | Chief Corporate Development & Digital Officer |
Dr. Yehia Hashad M.D. | Executive Vice President of Research & Development and Chief Medical officer |
Frederick J. Munsch | Senior Vice President, Controller & Chief Accounting Officer |
Jonathon L. Kellerman | Chief Compliance Officer |
T.J. Crawford | Chief Communications Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 26, 2024 | 4 | Filing |
Dec 26, 2024 | 4 | Filing |
Dec 26, 2024 | 4 | Filing |
Dec 26, 2024 | 4 | Filing |
Dec 26, 2024 | 4 | Filing |
Dec 26, 2024 | 4 | Filing |
Nov 01, 2024 | 8-K | Current Report |
Oct 30, 2024 | 10-Q | Quarterly Report |
Oct 30, 2024 | 8-K | Current Report |
Oct 04, 2024 | 4/A | [Amend] Filing |